Identification | Back Directory | [Name]
aderbasib | [CAS]
791828-58-5 | [Synonyms]
Incb7839 aderbasib INCB 007839 Unii-V9yl6nej3g (6S,7S)-Methyl 7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5- (6S,7S)-Methyl 7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-car Methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate (6S,7S)-Methyl 7-(hydroxycarbaMoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate 5-Azaspiro2.5octane-5-carboxylicacid, 7-(hydroxyaMino)carbonyl-6-(4-phenyl-1-piperazinyl)carbonyl-, Methylester, (6S,7S)- (6S,7S)-7-[(Hydroxyamino)carbonyl]-6-[(4-phenyl-1-piperazinyl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylic acid methyl ester | [Molecular Formula]
C21H28N4O5 | [MDL Number]
MFCD13195569 | [MOL File]
791828-58-5.mol | [Molecular Weight]
416.47 |
Chemical Properties | Back Directory | [density ]
1.38 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (240.11 mM; Need ultrasonic) | [form ]
Solid | [pka]
9.33±0.23(Predicted) | [color ]
White to light yellow |
Hazard Information | Back Directory | [Uses]
Aderbasib is a azaspiro[2.5]octanehydroxamide derivative as inhibitor of metalloproteases for the treatment of disorders such as cancer, arthritis, cardiovascular or skin disorders. | [in vivo]
Aderbasib (intraperitoneal injection; 50 mg/kg; 5 days per week beginning four weeks; 2 weeks) blocks glioma growth of SU-pcGBM2 NSG mice xenografts[1].INCB7839 can be formulated in 2% DMSO, 2% Tween 80, 48% PEG300, 48% water as a injection solution. This is for literature reference only[1]. Animal Model: | NSG mice[1] | Dosage: | 50 mg/kg | Administration: | Intraperitoneal injection; 50 mg/kg; 5 days per week beginning four weeks; 2 weeks | Result: | Robustly inhibited growth of pediatric glioblastoma orthotopic xenografts. |
| [IC 50]
ADAM10; ADAM17 | [storage]
Store at -20°C |
|
Company Name: |
BOC Sciences
|
Tel: |
1-631-485-4226; 16314854226 |
Website: |
https://www.bocsci.com |
|